Skip to main content

COVID-19

academics

 

Clinical research courses

  • Bayer to manufacture mRNA vaccine in Germany

    In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer of CureVac N.V., Franz-Werner Haas, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division, Stefan Oelrich, made the following statement  “Following discussions with the German government it has become clear that current manufacturing capacities for vaccines need to be increased, particularly for potential variants of the SARS-CoV-2 virus.

  • Private sector in COVID vaccination

    The private health sector is playing an important role in supplementing the activities of Government agencies in the on-going pan-India vaccination campaign to bring the COVID-19 pandemic under control.

  • CDSA Mission COVID Suraksha Project recruitment

    Translational Health Science and Technology Institute (THSTI) is an autonomous Institute of the Department of Biotechnology (DBT), Ministry of Science and Technology, Govt. of India. The institute is an integral part of the interdisciplinary NCR Biotech Science Cluster (NCR BSC) located at Faridabad, and is designed with the mission to conduct innovative translational research to translate concepts into products to improve human health.

  • Focus on management of adverse events in COVID-19 vaccination

    The operation guidelines prepared by the Central Government for the COVID-19 vaccination programme currently underway, provides a detailed roadmap to ensure a robust surveillance system to monitor adverse events post immunization and better understand the safety profile of the vaccines.

  • Inter-sectorial Convergence for COVID 19 vaccination

    As many as 19 Ministries and Departments of the Government of India are involved in the implementation of the national vaccination campaign that is currently underway to overcome the COVID-19 pandemic.

  • Applications are invited for the post of Research Assistant at AIIMS

    All-India Institute of Medical Sciences was established as an institution of national importance by an Act of Parliament with the objects to develop patterns of teaching in Undergraduate and Post-graduate Medical Education in all its branches so as to demonstrate a high standard of Medical Education in India; to bring together in one place educational facilities of the highest order for the training of personnel in all important branches of health activity; and to attain self-sufficiency in Post-graduate Medical Education.

  • Potential COVID-19 Drug Is Successful in Lab Study

    A new potential therapy for COVID-19 developed by researchers at Rush University Medical Center has shown success in preventing the disease’s symptoms in mice.

  • Nasal COVID-19 vaccine could soon be a reality

    In a significant development, Bharat Biotech has sought Drug Controller General India's (DCGI) approval to conduct nasal COVID-19 vaccine trials in India. The company has developed a new single-dose nasal COVID-19 vaccine in a partnership with Washington University in St Louis, USA. There are no intra-nasal COVID-19 vaccines under trial in India at the moment.

  • World’s largest COVID19 vaccination drive rolls out at India

    Today marks a momentous day in the COVID-19 trajectory of the country as India rolls out the world’s largest COVID-19 vaccination drive today. Hon. Prime Minister will launch the nationwide vaccination exercise at 10.30 am through video conference.

    This day also sees India’s total Active Caseload (2,11,033) further slump to account for just 2% of the total positive cases. The active cases were 2,10,120 last on 29th June 2021.

    The Total Recoveries have crossed 96% of the total cases, at 96.56%.

  • Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

    Pfizer and BioNTech SE announced that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer and BioNTech for COMIRNATY® (also known as BNT162b2), for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine earlier today.

Subscribe to COVID-19